{"id":176193,"date":"2023-11-17T10:22:59","date_gmt":"2023-11-17T16:22:59","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/11\/gene-editing-stocks-mixed-despite-worlds-first-crispr-drug"},"modified":"2023-11-17T10:22:59","modified_gmt":"2023-11-17T16:22:59","slug":"gene-editing-stocks-mixed-despite-worlds-first-crispr-drug","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/11\/gene-editing-stocks-mixed-despite-worlds-first-crispr-drug","title":{"rendered":"Gene editing stocks mixed despite world\u2019s first CRISPR drug"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/gene-editing-stocks-mixed-despite-worlds-first-crispr-drug.jpg\"><\/a><\/p>\n<p>There were mixed reactions across gene editing space on Thursday after CRISPR Therapeutics (NASDAQ: <a href=\"https:\/\/seekingalpha.com\/symbol\/CRSP\" title=\"CRISPR Therapeutics AG\">CRSP<\/a>) and Vertex Pharmaceuticals (NASDAQ: <a href=\"https:\/\/seekingalpha.com\/symbol\/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\">VRTX<\/a>), in a world\u2019s first, won U.K. approval for their CRISPR-based drug exa-cel for sickle cell disease and beta-thalassemia.<\/p>\n<p>CRISPR Therapeutics (<a href=\"https:\/\/seekingalpha.com\/symbol\/CRSP\" title=\"CRISPR Therapeutics AG\">CRSP<\/a>) has added ~5%, and MaxCyte (NASDAQ: <a href=\"https:\/\/seekingalpha.com\/symbol\/MXCT\" title=\"MaxCyte, Inc.\">MXCT<\/a>), which has a licensing deal with the Swiss biotech, has gained ~4%. Vertex Pharma (<a href=\"https:\/\/seekingalpha.com\/symbol\/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\" class=\"\">VRTX<\/a>) is trading lower for the third straight session.<\/p>\n<p>Other CRSPR-based drug developers Graphite Bio (<a href=\"https:\/\/seekingalpha.com\/symbol\/GRPH\" title=\"Graphite Bio, Inc.\">GRPH<\/a>) and Precision BioSciences (<a href=\"https:\/\/seekingalpha.com\/symbol\/DTIL\" title=\"Precision BioSciences, Inc.\">DTIL<\/a>) are also among the gainers, while notable gene editing biotechs Editas Medicine (<a href=\"https:\/\/seekingalpha.com\/symbol\/EDIT\" title=\"Editas Medicine, Inc.\">EDIT<\/a>), Beam Therapeutics (<a href=\"https:\/\/seekingalpha.com\/symbol\/BEAM\" title=\"Beam Therapeutics Inc.\">BEAM<\/a>), Intellia Therapeutics (<a href=\"https:\/\/seekingalpha.com\/symbol\/NTLA\" title=\"Intellia Therapeutics, Inc.\">NTLA<\/a>), and Verve Therapeutics (<a href=\"https:\/\/seekingalpha.com\/symbol\/VRTX\" title=\"Vertex Pharmaceuticals Incorporated\">VRTX<\/a>) are in the red.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>There were mixed reactions across gene editing space on Thursday after CRISPR Therapeutics (NASDAQ: CRSP) and Vertex Pharmaceuticals (NASDAQ: VRTX), in a world\u2019s first, won U.K. approval for their CRISPR-based drug exa-cel for sickle cell disease and beta-thalassemia. CRISPR Therapeutics (CRSP) has added ~5%, and MaxCyte (NASDAQ: MXCT), which has a licensing deal with the [\u2026]<\/p>\n","protected":false},"author":511,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1902,11],"tags":[],"class_list":["post-176193","post","type-post","status-publish","format-standard","hentry","category-bioengineering","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/176193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/511"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=176193"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/176193\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=176193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=176193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=176193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}